Opaleye Management Inc. purchased $136K of GRCE (indirect holdings)
Opaleye Management Inc. purchased 71,065 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at an average of $1.92 ($1.89–$1.95, $0.14M total) across 3 trades over 2026-10-14 to 2026-10-16.
How this was made
The 30-second read
Why it matters
While the purchase is modest, the buyer's status as a 10% owner may be interpreted as a vote of confidence, but the overall market impact is expected to be limited.
Market read
A small insider buy that may slightly buoy the stock but is unlikely to drive significant price movement.
What to watch
Potential upcoming clinical milestones for Grace Therapeutics that may have prompted the purchase.
Background
Form 4 filings provide transparent disclosure of insider transactions, used by traders to gauge insider sentiment.
Ticker impact
SEC Form 4 disclosed Opaleye Management Inc. bought 71,065 shares of Grace Therapeutics for $136K, increasing its stake to 2.94M shares.
modest upward pressure as the market prices in the insider's confidence
The transaction size is small relative to market cap, but the buyer is a significant owner, which can be viewed positively by investors.
Market effects
Limited impact on the biotech sector; insider activity is routine.
No discernible regional effect.
Minimal; the filing is company‑specific.
Counterpoint
The purchase could be a tactical move unrelated to fundamentals, offering no real upside.
Key entities
- companyGrace Therapeutics, Inc.
Biotech firm whose shares were purchased.
- insiderOpaleye Management Inc.
10% owner executing the purchase.
